The Valley Desk

NCT03700320 · Interventional trial

Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine

Overall registry status Completed

Phase 3

Conditions Episodic Migraine

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov